Stakeholders Seek More Support for Biosimilars

FDA Commissioner Scott Gottlieb repeated the agency’s commitment to biosimilars and stakeholders urged the agency to do more to improve market access during a public meeting Tuesday.

Gottlieb expressed dissatisfaction with the current state of biosimilar access, noting that not even half of the approved products have entered the market. He also reaffirmed the agency’s commitment to discouraging gaming of biosimilar competition within the industry.

Gottlieb has previously said the system is “rigged” against biosimilars.